Nearly 95% of JMML patients have somatic or germline mutations in genes encoding proteins that activate the RAS/MAPK pathway (NF1, CBL, NRAS, KRAS, RRAS, RRAS2, FLT3, PTPN11) [1, 4]. The gene discussed is NF1; the disease is juvenile myelomonocytic leukemia.